The 3 most recent market catalysts affecting $VRCA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Verrica Pharmaceuticals Announces Completed Enrollment In COVE-2 Pivotal Phase 3 Trial Of YCANTH For Common Warts; Says Topline Data Expected In Q1 2027
This announcement is a moderate corporate catalyst for Verrica Pharmaceuticals. Completing enrollment in a pivotal Phase 3 trial is a critical de-risking event, moving the drug clo…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Verrica Pharmaceuticals' Q2 earnings report reveals a concerning trend: a substantial miss on adjusted EPS and a significant year-over-year decline in both EPS and sales. While the…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
Verrica Pharmaceuticals has entered into an agreement with Medomie Pharma, granting them exclusive rights to obtain marketing authorization and distribute YCANTH in Israel. This de…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.